Literature DB >> 25758911

Factors to consider when selecting a nebulizer for a new inhaled drug product development program.

Mark Elphick1, Dirk von Hollen, John N Pritchard, Kurt Nikander, Lucy E A Hardaker, Ross H M Hatley.   

Abstract

INTRODUCTION: Nebulizers are a common device choice for use when developing a new drug product, but the range of nebulizer devices available can make it difficult to select the right device. Increasingly, companies are only able to promote a drug with the device that was used during the development program; therefore, choosing the best device at an early stage is important in order to achieve commercial success. Selecting a device that is inappropriate for the intended drug can result in poor drug delivery from the nebulizer to the patient, which would have obvious implications for the development program. As device performance varies, it is important to ensure that the most appropriate device is chosen for the intended drug to ensure optimal drug delivery to the patient population. AREAS COVERED: In this review, the types of nebulizer devices available are highlighted, and the factors that should be taken into consideration when selecting the most appropriate device for a new drug are discussed. The review is broadly divided into drug, device, patient and trial characteristics. EXPERT OPINION: Efficient nebulizer devices that combine electronic monitoring capabilities as a form of telehealth are likely to provide superior drug delivery to patients and accurate clinical trial data. Their use in adaptive clinical trials may help to vastly reduce the time and costs associated with achieving drug approval.

Entities:  

Keywords:  adherence; clinical trials; drug formulations; electronic monitors; nebulizer; therapeutic window

Mesh:

Substances:

Year:  2015        PMID: 25758911     DOI: 10.1517/17425247.2015.1014339

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  3 in total

Review 1.  Molecular Insight into the Therapeutic Effects of Stem Cell-Derived Exosomes in Respiratory Diseases and the Potential for Pulmonary Delivery.

Authors:  Mohammad H Azhdari; Nima Goodarzi; Mohammad Doroudian; Ronan MacLoughlin
Journal:  Int J Mol Sci       Date:  2022-06-03       Impact factor: 6.208

2.  Characterization and comparison of Re-Du-Ning aerosol particles generated by different jet nebulizers.

Authors:  Yi Zhang; Brian Chi-Yan Cheng; Cui Li; Yonghua Tao; Chanjuan Yu; Xinyue Liu; Xiaoyan Gao; Gan Luo
Journal:  RSC Adv       Date:  2019-09-25       Impact factor: 4.036

3.  Intratumoral submicron particle docetaxel inhibits syngeneic Renca renal cancer growth and increases CD4+, CD8+, and Treg levels in peripheral blood.

Authors:  Holly A Maulhardt; Alyson M Marin; Gere S diZerega
Journal:  Invest New Drugs       Date:  2020-03-20       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.